11 results
Primary: To determine the response of 2B3-101 treatment as single agent or in combination with trastuzumab in patients with LM from breast cancer using the LM response scoreSecundary: - To determine the safety profile in patients with LM treated…
The purpose of this study is to observe the usability of Dexmedetomidine and to determine the overall satisfaction of the patient.
The trial is designed as an open-label pilot study. The main goal is to investigate if bezafibrate can reduce VLCFA in vivo in patient with X-ALD. If there is indeed a biochemical effect, a large follow-up study will be initiated with clinical…
Primary objective:To evaluate the efficacy of F13640 in spinal cord injury patients with moderate to severe central neuropathic pain, when administered for 12 weeks including a 7-day titration period. Main secondary objectives:To evaluate pain…
The primary objective of the study is to investigate whether the IDD (Intervertebral Differential Dynamics) protocol with Accu-Spina on the VAS low back pain score at 3 months posttreatment.
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB074 in subjects with neuropathic PLSR.
Both interventions (GRAIL training & endurance and strength training (control intervention)) will result in an increase in gait speed, functional walking ability and social participation. However, the GRAIL training will result in larger…
The primary objective of the study is to evaluate the efficacy of 2 dose regimens of BIIB074 on neuropathic pain in subjects with PLSR.A secondary objective is to evaluate the efficacy of 2 dose regimens of BIIB074 on additional neuropathic pain…
The primary objective of this study is:* To assess the safety and tolerability of TPN-101 in patients with C9ORF72 ALS/FTDThe exploratory objectives of this study are:* To assess the concentrations of TPN-101 in plasma and cerebrospinal fluid (CSF…
This study has been transitioned to CTIS with ID 2023-510007-22-00 check the CTIS register for the current data. NMOSD is associated with a high degree of disability and mortality, and there is a unmet medical need in children with this disease.…
To test whether monthly infusions (every four weeks) of intravenous Flebogamma® 5% DIF in a 1 year treatment period in PPS subjects are superior to placebo by assessing physical performance, as measured by 2MWD.For Stage 1, to select the optimal…